Перейти к содержанию

Biomarin Pharmaceutical Inc (BMRN) stock: revenue, earnings & dividend

Biomarin Pharmaceutical Inc (BMRN, Nasdaq): revenue, earnings, dividend and balance sheet from official SEC filings.

Stock screener BMRN · Nasdaq Pharma & Biotech US-CA

Key figures

Fiscal year
2025
Revenue
3.22 bn $
Revenue growth
12.9 %
Revenue growth 5y (p.a.)
11.6 %
Net income
349 m $
Net margin
10.8 %
Operating margin
12.7 %
Earnings per share (diluted)
1.80 $
Dividend per share
–
Payout ratio
–
Consecutive dividend years
–
Consecutive dividend raises
–
Dividend growth 5y (p.a.)
–
Total assets
7.59 bn $
Equity
6.09 bn $
Equity ratio
80.2 %
Return on equity
5.7 %
Cash
1.31 bn $
Operating cash flow
828 m $
Free cash flow
725 m $
Shares outstanding
193,694,734

History

Revenue by fiscal year

2016 1.12 bn $
2017 1.31 bn $
2018 1.49 bn $
2019 1.7 bn $
2020 1.86 bn $
2021 1.85 bn $
2022 2.1 bn $
2023 2.42 bn $
2024 2.85 bn $
2025 3.22 bn $

Net income by fiscal year

2016 -630.21 m $
2017 -117.04 m $
2018 -77.21 m $
2019 -23.85 m $
2020 854 m $
2021 -64.1 m $
2022 142 m $
2023 168 m $
2024 427 m $
2025 349 m $
YearRevenueNet incomeEPSDividend per shareOperating cash flow
20253.22 bn $349 m $1.80 $–828 m $
20242.85 bn $427 m $2.21 $–573 m $
20232.42 bn $168 m $0.87 $–159 m $
20222.1 bn $142 m $0.75 $–176 m $
20211.85 bn $-64.1 m $-0.35 $–305 m $
20201.86 bn $854 m $4.50 $–85.4 m $
20191.7 bn $-23.85 m $-0.13 $–48.3 m $
20181.49 bn $-77.21 m $-0.44 $–20.2 m $
20171.31 bn $-117.04 m $-0.67 $–-8.76 m $
20161.12 bn $-630.21 m $-3.81 $–-227.84 m $

Data from XBRL filings at the SEC, processed automatically, no guarantee. Not investment advice. All filings at the SEC (EDGAR)